- Home
- NITO vs TRAW Comparison
NITO vs TRAW Comparison
Compare NITO & TRAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NITO
- TRAW
- Stock Information
- Founded
- NITO 2009
- TRAW 1998
- Country
- NITO Israel
- TRAW United States
- Employees
- NITO N/A
- TRAW N/A
- Industry
- NITO
- TRAW
- Sector
- NITO
- TRAW
- Exchange
- NITO NYSE
- TRAW NYSE
- Market Cap
- NITO 7.8M
- TRAW 7.8M
- IPO Year
- NITO N/A
- TRAW 2013
- Fundamental
- Price
- NITO $0.24
- TRAW $1.40
- Analyst Decision
- NITO
- TRAW
- Analyst Count
- NITO 0
- TRAW 0
- Target Price
- NITO N/A
- TRAW N/A
- AVG Volume (30 Days)
- NITO 1.2M
- TRAW 3.4M
- Earning Date
- NITO 08-13-2025
- TRAW 08-14-2025
- Dividend Yield
- NITO N/A
- TRAW N/A
- EPS Growth
- NITO N/A
- TRAW N/A
- EPS
- NITO N/A
- TRAW N/A
- Revenue
- NITO $232,000.00
- TRAW $227,000.00
- Revenue This Year
- NITO N/A
- TRAW $3.81
- Revenue Next Year
- NITO N/A
- TRAW $30.43
- P/E Ratio
- NITO N/A
- TRAW N/A
- Revenue Growth
- NITO 24.74
- TRAW 0.44
- 52 Week Low
- NITO $0.16
- TRAW $0.97
- 52 Week High
- NITO $3.49
- TRAW $19.44
- Technical
- Relative Strength Index (RSI)
- NITO 42.39
- TRAW 42.63
- Support Level
- NITO $0.23
- TRAW $1.62
- Resistance Level
- NITO $0.26
- TRAW $1.77
- Average True Range (ATR)
- NITO 0.02
- TRAW 0.15
- MACD
- NITO -0.00
- TRAW -0.03
- Stochastic Oscillator
- NITO 14.95
- TRAW 10.34
About NITO N2OFF INC
N2OFF Inc is a pioneering agri-food tech company dedicated to developing sustainable solutions for the plant-based food industry. Operating through two subsidiaries, it delivers integrated solutions for enhanced safety, quality, and sustainability from field to fork. The Company has two reportable segments: Pathogen prevention and prolong shelf life, and the N2O emissions Global warming solutions.
About TRAW TRAWS PHARMA INC
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.